These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22099764)

  • 1. Effect of exenatide on gastric emptying and graft survival in islet allograft recipients.
    Peixoto EM; Froud T; Gomes LS; Zavala LM; Corrales A; Herrada E; Ricordi C; Alejandro R
    Transplant Proc; 2011 Nov; 43(9):3231-4. PubMed ID: 22099764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction.
    Faradji RN; Froud T; Messinger S; Monroy K; Pileggi A; Mineo D; Tharavanij T; Mendez AJ; Ricordi C; Alejandro R
    Cell Transplant; 2009; 18(10):1247-59. PubMed ID: 20003758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
    Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.
    Faradji RN; Tharavanij T; Messinger S; Froud T; Pileggi A; Monroy K; Mineo D; Baidal DA; Cure P; Ponte G; Mendez AJ; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Dec; 86(12):1658-65. PubMed ID: 19104401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
    Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
    PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
    Kolterman OG; Kim DD; Shen L; Ruggles JA; Nielsen LL; Fineman MS; Baron AD
    Am J Health Syst Pharm; 2005 Jan; 62(2):173-81. PubMed ID: 15700891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice.
    Crutchlow MF; Yu M; Bae YS; Deng S; Stoffers DA
    Transplant Proc; 2008 Jun; 40(5):1650-7. PubMed ID: 18589167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
    Ghazi T; Rink L; Sherr JL; Herold KC
    Diabetes Care; 2014; 37(1):210-6. PubMed ID: 23939544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
    Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
    Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation.
    Park YJ; Ao Z; Kieffer TJ; Chen H; Safikhan N; Thompson DM; Meloche M; Warnock GL; Marzban L
    Diabetologia; 2013 Mar; 56(3):508-19. PubMed ID: 23262664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
    Camastra S; Astiarraga B; Tura A; Frascerra S; Ciociaro D; Mari A; Gastaldelli A; Ferrannini E
    Diabetes Obes Metab; 2017 Mar; 19(3):412-420. PubMed ID: 27898183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.
    Zoso A; Serafini P; Lanzoni G; Peixoto E; Messinger S; Mantero A; Padilla-Téllez ND; Baidal DA; Alejandro R; Ricordi C; Inverardi L
    PLoS One; 2016; 11(6):e0157245. PubMed ID: 27285580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.
    Cersosimo E; Gastaldelli A; Cervera A; Wajcberg E; Sriwijilkamol A; Fernandez M; Zuo P; Petz R; Triplitt C; Musi N; DeFronzo RA
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1763-70. PubMed ID: 21411546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.
    Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Crouch B; Jones KL; Horowitz M; Rayner CK
    Diabetes; 2016 Jan; 65(1):269-75. PubMed ID: 26470783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
    Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
    Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.